CIK 0001651308 · Large accelerated filer
BeOne Medicines Ltd.
Sign in to watch- Ticker
- BEIGF
- Exchange
- Nasdaq, OTC
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981209416
- Phone
- 41-616851900
- Business address
- C/O BEONE MEDICINES I GMBH, AESCHENGRABEN 27, 21ST FLOOR, BASEL, Switzerland, 4051
- Former names
- BeiGene, Ltd.
Securities
- ONC American Depositary Shares Nasdaq
- BEIGF Common stock OTC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $48,487,541
- in 9 filings, $47.8M under 10b5-1 plans
Net −$48,487,541. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-11-11 | OYLER JOHN Chief Executive Officer | Gift | −151,320 | 7,299,574 | ||
| 2025-11-07 | Wang Xiaodong Director | Gift | −424,073 | 4,582,601 | ||
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −1,112 | $350.00 | $389K | 0 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +302 | $194.47 | $59K | 302 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +8,961 | $213.32 | $1.9M | 9,263 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +296 | $159.03 | $47K | 9,559 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −664 | $347.82 | $231K | 8,895 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −4,733 | $350.22 | $1.7M | 4,162 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −4,162 | $351.12 | $1.5M | 0 |
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −3,926 | 39,624 | ||
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −116,493 | 109,109 | ||
| 2025-10-08 | Lee Chan Henry SVP, General Counsel | Option exercise · Share Option (Right to Buy) 10b5-1 | −3,848 | 127,062 | ||
| 2025-09-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −4,066 | $324.12 | $1.3M | 23,737 |
| 2025-09-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −6,883 | $325.06 | $2.2M | 16,854 |
| 2025-09-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −12,446 | $326.14 | $4.1M | 4,408 |
| 2025-09-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −4,008 | $326.90 | $1.3M | 400 |
| 2025-09-16 | OYLER JOHN Chief Executive Officer | Sale 10b5-1 | −400 | $327.78 | $131K | 0 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Sale 10b5-1 | −1,112 | $325.00 | $361K | 0 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +6,802 | $194.47 | $1.3M | 6,802 |
| 2025-09-10 | Lee Chan Henry SVP, General Counsel | Option exercise 10b5-1 | +1,796 | $213.32 | $383K | 8,598 |
Page 19 of 71 · 1,406 trades